However, several studies aimed to investigate the effectiveness of newer agents, such as glucagon-like peptide 1 receptor agonists (GLP1-ras) or sodium-glucose co-transporter 2 inhibitors (SGLT2-is), regarding beneficial effects on NAFL disease (NAFLD). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.